EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATAD2 drives immunotherapy resistance by promoting lactic acid-mediated CD8+ T cell dysfunction in lung adenocarcinoma

Wanfeng Gao, Jialei Xu, Yue Li, Jingchang Zhang, Chenghao Ma, Junfeng Chen, Jiajing Chen

Frontiers in Immunology · 19.03.2026 · 17

DOI: 10.3389/fimmu.2026.1800533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 19.03.2026. Verfasst von Wanfeng Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lactic Acid, Lung Neoplasms, ATPases Associated with Diverse Cellular Activities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

T cell-based immunotherapies have improved outcomes in lung adenocarcinoma (LUAD), yet many patients develop primary or acquired resistance. Tumor-intrinsic mechanisms that suppress CD8 + T cell function remain incompletely understood.

Methods

Public LUAD transcriptomic datasets were analyzed to assess the association of ATPase family AAA domain-containing protein 2 (ATAD2) with prognosis and immune infiltration. Atad2 -deficient LUAD cell lines were generated using CRISPR/Cas9 and co-cultured with activated CD8 + T cells to evaluate cytotoxicity, cytokine production, PD-1 expression and survival. The mediating role of lactic acid (LA) was confirmed using conditioned medium exposure, exogenous LA supplementation, and LDHA overexpression rescue experiments. ATAD2-mediated transcriptional regulation of LDHA was investigated by ChIP-qPCR and c-Myc overexpression. Subcutaneous tumor models were used to determine the effects of Atad2 deletion on LA accumulation, CD8 + T cell infiltration, tumor growth, and response to anti-PD-1 therapy.

Results

ATAD2 was significantly upregulated in LUAD and correlated with poor survival and decreased CD8 + T cell infiltration. Atad2 deletion enhanced CD8 + T cell function and survival, effects reversed by exogenous LA. Mechanistically, ATAD2 enhanced c-Myc-dependent LDHA transcription, leading to increased lactic acid production and an immunosuppressive microenvironment. LDHA overexpression restored LA levels and reversed the immune-activating effects of Atad2 loss. In vivo , Atad2 deficiency reduced intratumoral LA, remodeled the immunosuppressive microenvironment, increased CD8 + T cell infiltration, inhibited tumor growth, and improved sensitivity to anti-PD-1 therapy.

Conclusions

ATAD2 drives immunotherapy resistance in LUAD by activating an ATAD2-LDHA-LA axis that impairs CD8 + T cell function. Targeting ATAD2 may broadly restore antitumor immunity and enhance the efficacy of T cell-based immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLactic AcidLung NeoplasmsATPases Associated with Diverse Cellular ActivitiesCD8-Positive T-LymphocytesHumansImmunotherapyMetabolic ReprogrammingAnimalsMiceCell Line, TumorMice, Inbred C57BLDNA-Binding Proteins

Stichwörter der Autor:innen

ATAD2LDHAT cell therapy resistancelactic acidlung adenocarcinoma

Substanzen

Lactic AcidATAD2 protein, humanATPases Associated with Diverse Cellular ActivitiesATAD2 protein, mouseDNA-Binding Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China.
  • College of Medicine, Nankai University, Tianjin, China.
  • Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, China.
  • Tianjin University Central Hospital, Tianjin University, Tianjin, China.
  • Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin Institute of Hepatobiliary Disease, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, China.

Zitieren

APA

Gao, W., Xu, J., Li, Y., Zhang, J., Ma, C., Chen, J., & Chen, J. (2026). ATAD2 drives immunotherapy resistance by promoting lactic acid-mediated CD8+ T cell dysfunction in lung adenocarcinoma. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1800533

Vancouver

Gao W, Xu J, Li Y, Zhang J, Ma C, Chen J, et al. ATAD2 drives immunotherapy resistance by promoting lactic acid-mediated CD8+ T cell dysfunction in lung adenocarcinoma. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1800533

BibTeX
@article{Gao2026,
  author = {Gao, Wanfeng and Xu, Jialei and Li, Yue and Zhang, Jingchang and Ma, Chenghao and Chen, Junfeng and Chen, Jiajing},
  title = {ATAD2 drives immunotherapy resistance by promoting lactic acid-mediated CD8+ T cell dysfunction in lung adenocarcinoma},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1800533}
}
Kostenlos starten →